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Abstract 
Vascular-targeted nanocarriers are an attractive option for the treatment of a number of 
cardiovascular diseases, as they allow for more specific delivery and increased efficacy of many small 
molecule drugs. However, immune clearance, limited cellular uptake, and particle-cell dynamics in 
blood flow can hinder nanocarrier efficacy in many applications. This review aims to investigate 
successful strategies for the use of vascular-targeted nanocarriers in the treatment of cardiovascular 
diseases such as atherosclerosis. In particular, the review will highlight strategies employed for 
actively targeting the components of the atherosclerotic plaque, including endothelial cells, 
macrophages, and platelets and passive targeting via endothelial permeability, as well as design 
specifications (such as size, shape, and density) aimed at enhancing the ability of nanocarriers to 
reach the vascular wall. 
Introduction 
Targeted nanocarriers (NCs) for drug delivery remain an attractive option for improving the 
efficacy of a number of drug molecules. In principle, targeted NCs are drug-loaded, nanoscale 
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particles with surface-linked targeting moieties that are able to safely navigate the vasculature and 
bind to a specific target, where they are able to release their drug payload for a local therapeutic 
effect. This disease site drug release, rather than a systemic release, increases drug efficacy and 
decreases systemic side effects. In many cases, NCs are targeted specifically to the vascular wall due 
to the intimate involvement of the cells of the vascular wall in the pathogenesis of a variety of 
diseases. However, like any strategy, there are limitations to the use of targeted NCs in drug 
delivery. For one, nanocarriers may undergo phagocytosis by immune cells, may be cleared by the 
liver, or may be unable to marginate (travel) to the vascular wall to reach their targets as effectively 
as micron-sized carriers. (See Sidebar: The Margination Problem).1 Furthermore, it is often not 
enough to simply reach a target on the vascular side; in order to be effective, it is frequently 
necessary for NCs to cross the endothelium to allow the drug payload to be delivered directly to the 
tissue. Given the variety of challenges present in achieving a successful targeted drug delivery 
system, there are a number of decisions to be made in the design process. This review will highlight 
successful strategies for design of vascular-targeted NCs (and, to some extent, microcarriers) 
focused on enhanced margination, avoidance of immune clearance, and transmigration from the 
vascular wall to the diseased tissue space with specific focus on atherosclerosis and other 
cardiovascular diseases. 
Nanoparticles for Vascular-Targeting in Atherosclerotic Plaques  
Overview of Atherosclerotic Pathogenesis  
Cardiovascular disease (CVD) is the leading cause of death worldwide. Atherosclerosis is the 
most common type of CVD, often resulting in a stroke or heart attack. It is characterized by the 
progressive formation and rupture of plaques in the arterial wall associated with inflammation and 
endothelial dysfunction.2 These plaques often originate as a result of injury to the endothelium, 
which can be caused by risk factors such as hypertension (high blood pressure) and smoking.3 Once 
injured, the ECs begin exhibiting an inflammatory phenotype, recruiting macrophages to the area 
and expressing endothelial adhesion molecules. As chemokines (such as monocyte chemoattractant 
protein-1 and macrophage colony-stimulating factor) are produced, monocytes and leukocytes bind 
to the damaged endothelium and extravasate into the tissue space. Monocytes then differentiate 
into macrophages, professional phagocytes recruited to take up excess lipids accumulating at the 
injury site. The atherosclerotic plaque itself consist of lipids, inflamed endothelial cells, 
macrophages, foam cells (resulting from macrophage uptake of oxidized LDL), vascular smooth 
muscle cells (which further recruit leukocytes and increase endothelial dysfunction), and several 
other components that accumulate over time, leading to calcification and thrombus formation. The 
accumulated lipids are oxidized by a number of enzymes, leading to tissue damage, release of pro-
inflammatory chemokines, and hence increased leukocyte and platelet adhesion via 
upregulated/overexpressed adhesion molecules.  
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 Throughout the disease progression, numerous atherosclerotic biomarkers and 
characteristics can aid in vascular-targeted drug delivery. Several studies have evaluated the ability 
of drug carriers to deliver imaging agents and therapeutics to the vascular tissue in atherosclerosis. 
Macrophages and endothelial cells have served as the two main cell targets because of their specific 
expression of inflammatory molecules (such as E-selectin, P-selectin, ICAM, and VCAM-1) and 
attributes (e.g. “leaky” vasculature exhibited by endothelial cells). Table 1 provides a brief summary 




“Passive” targeting of cardiovascular disease sites 
Enhanced Vascular Permeability  
One main mechanism exploited for passive targeting of diseased vessels is through the 
enhanced permeability of the endothelium in inflammation. This effect, long investigated in the 
context of cancer therapy, is assumed to be present to some extent in atherosclerosis due to the 
prominent involvement of inflammation in disease progression.  In addition, the intima of the plaque 
is reported to contain leaky microvessels rapidly formed due to the growing atherosclerotic 
plaque.4,5 This combination of increased vascular permeability and leaky microvessels in theory 
should allow NCs to permeate the vascular wall and accumulate within the diseased tissue. 
However, only limited works have explored this possibility. Kim et al. examined the influence of 
endothelial permeability on lipid-polymer hybrid nanoparticle translocation using an endothelialized 
microfluidic device and an in vivo atherosclerotic rabbit model. The permeability of the endothelium 
in vitro was modified through TNF-α stimulation and varying shear stress. The authors find that 
increases in nanoparticle translocation correlated with enhanced permeability.6 Similarly, Lobatto et 
al. conducted in vivo and ex vivo atherosclerotic rabbit experiments to elucidate the destination of 
long-circulating liposomal nanoparticles7 and found liposomal nanoparticles to accumulate within 
plaques due to enhanced permeability. From tracking liposomal nanoparticles over time, it was 
determined that they enter through the luminal side and disperse throughout the plaque. However, 
Kim et al. and Lobatto et al. only examined one specific size each (70nm and 123nm, respectively), so 
it would be important to understand the effect of particle size on these results, as it has been 
established that size has a great impact on carrier transport across the endothelium. 
One critical issue when relying on passive accumulation due to leaky 
endothelium/microvessels is the clearance of NCs before exposure to diseased tissue. In this 
context, developers of NCs have employed poly (ethylene glycol) (PEG) in particle design. PEG is a 
highly flexible, hydrophilic polymer that when grafted onto a surface creates a hydration layer that 
effectively reduce protein adsorption onto the surface, which is a critical component of immune 
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recognition and clearance – hence PEG increases circulation time.8 Applying this principle, Zhang et 
al. fabricated nanoparticles consisting of poly (lactic-co-glycolic acid) (PLGA) and PEG chains that 
encapsulated a liver X receptor (LXR) agonist aimed to target macrophages within atherosclerotic 
plaques to control LXR gene expression. The LXR gene in macrophages is responsible for regulating 
inflammation and lipid metabolism.9 The objective of this study was to promote gene expression 
within plaques but not in the liver, which was the main drawback of free LXR agonist leading to 
hepatic steatosis. Ultimately, the PLGA-PEG nanoparticles encapsulating the LXR agonist were able 
to reduce the amount of macrophages in plaques by about 50% without increasing the 
concentration of lipids in the liver and plasma compared to free LXR agonist.9 Another study used 
PEG-coated ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles as an imaging agent for 
areas of inflammation, particularly atherosclerotic plaques.10 They found that PEGylation allowed 
their particles to evade immune clearance such that they were able to accurately detect plaque 
formation.   
It is important to note that shape may be combined with PEGylation to further enhance long 
circulation.  Specifically, Geng et al. showed that worm micelles constructed from PEG-based diblock 
copolymer amphiphiles exhibit long circulation and enhance tumor localization largely due slower 
action of tissue macrophages.11 However, two key issues have emerged in recent years with the use 
of PEG. For one, the presence of PEG on NCs has been shown to interfere with cellular 
internalization. Secondly, there is evidence of immune response to PEG where a PEG-specific 
antibody is generated upon the first introduction of PEG NCs in vivo, which leads to rapid clearance 
of the particles upon repeat dosing. A comprehensive review of these issues and ways to circumvent 
can be found in work by Amoozgar and Yeo.12  
In search for a more effective alternative to PEG coatings, researchers have begun to look 
toward zwitterionic coatings to protect particles from protein adsorption and immune clearance. 
Zwitterionic materials are able to strongly bind water molecules via electrostatic interactions, 
creating high degrees of hydration and thus protecting the surface from protein adsorption.13 To 
date, NCs coated in zwitterionic materials have been investigated to determine their circulation time 
and in vivo clearance. Xiao et al. prepared magnetite particles coated with both polyacrylic acid 
(PAA) and zwitterionic coating comprised of PAA reacted with 3-(dimethylamino)propylamine 
(DEAPA) designed to function as MRI blood pool contrast agents.14 The zwitterionic particles 
exhibited greatly reduced macrophage uptake as well as a greater-than-threefold increase in 
circulation half-life. Similarly, Sun et al. developed quantum dots with a zwitterionic coating, and 
compared their biodistribution, uptake, and circulation times with similar PEGylated quantum dots.15 
They found that the zwitterionic coating resulted in a much longer circulation half-life (t1/2 = 21 ± 1hr 
for the zwitterionic coating compared to t1/2 = 6.4 ± 0.5 minutes for the PEG coating), and greatly 
decreased accumulation in the liver and spleen. The increased circulation time of zwitterion-coated 
NCs could prove to be very useful in the design of NCs for the treatment of atherosclerosis, as it 
could result in greater accumulation in plaques, but studies evaluating their effectiveness in this 
context are yet to be done. A comprehensive study of the zwitterion coating on nanoparticle 
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degradation and drug release from typical biomaterials, such as PLGA, would also be necessary for 
these novel coatings to eventually translate to widespread clinical application.  
Magnetically Guided Nanoparticles 
One interesting “pseudo-passive” targeting approach that can potentially take advantage of 
the enhanced vascular permeability effect, perhaps more fully, is the use of magnetically guided 
NCs. In theory, the use of magnetic nanoparticles allows for the application of an external magnetic 
field, which can guide nanoparticles specifically to the disease site, improving margination and 
accumulation within diseased tissue.16 This strategy has previously been studied extensively in the 
context of tumor targeting and recent evidence suggests that this strategy can prove to be beneficial 
in cardiovascular disease as well. Simulations by Freund et al. have shown that applying a magnetic 
force both parallel and perpendicular to the blood vessel will attract magnetic particles to the vessel 
wall. The external magnetic field assists in transporting particles from the cell-free layer, which lacks 
red blood cells and, thus, margination-inducing collisions, to the vessel wall.17 This increased 
margination toward the vessel wall can allow for increased accumulation within leaky vasculature, or 
increase the amount of time for a given particle to bind to its target. Such simulations are backed up 
by experimental evidence, as well. Chorny et al. used magnetic nanoparticles made by controlled 
precipitation of calcium oleate in the presence of magnetic-based ferrofluid for the delivery of 
antioxidant enzymes to endothelial cells in vitro.18 The results of the study showed that the 
internalization of the nanoparticles by HUVEC cells increased from 3-8% for the cells treated with 
particles without the presence of the magnetic field to 46-71% for the case of cells under the 
exposure of the magnetic field. Fluorescent microscopy also validated the hypothesis of increased 
cell uptake of nanoparticles in the presence of the magnetic field. The therapeutic effect of these 
particles was studied by quantification of recovery of HUVEC cells after exposure to 10 mM 
hydrogen peroxide for 5 h. Their results indicated average recovery of 62% for cells treated with 
magnetic particles under the exposure of magnetic field while the recovery in the absence of the 
magnetic field remained under 20%. Another study by Chorny et al. used zinc oleate-based magnetic 
nanoparticles for gene delivery to stented arteries.19 Their results indicated that the gene expression 
in the rat carotid model of stent angioplasty was 8-14 fold higher in magnetically treated animals in 
comparison to non-magnetic controls even 9 days after the treatment. Mannell et al. used 
perfluorocarbon-filled lipid microbubbles associated with iron magnetic particles for gene delivery to 
the endothelium.20 These microbubbles were directed toward the target site using an external 
magnetic field. Their results also demonstrated increased uptake of nanoparticles by HMEC 
endothelial cells after exposure to the external magnetic field. Forbes et al. have proposed the idea 
of developing stent modified with magnetic coating for implanting at the disease sites to capture 
magnetic nanoparticles.21 These stents can be activated with a magnetic field to capture magnetic 
nanoparticles. In this study, the stainless steel stents were coated with cobalt nickel alloy. In vivo 
experiments using a rat model indicated the magnetic nanoparticles preferentially accumulated in 
the region around the implanted stent. Utilizing these stents can be a practical method for 
introducing the magnetic field in the diseased site for transition to the in vivo systems. 
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A recent computational study by Chandramouli et al. has introduced the idea of using super 
paramagnetic iron oxide particles to destroy atherosclerotic plaques via hyperthermia.22 These 
magnetic particles can be guided to the plaque site using an external magnetic field, and then 
heated by rapid switching of the magnetic field, creating a spin on the particles. This spinning will 
give off heat, reducing the hardness of the plaque due to its thermal expansion, which can 
consecutively lead to abrasion of the plaque. Their calculations demonstrated an increase in the 
plaque removal rate by increasing particle mass flow rate and velocity.  However, such abrasion of 
plaque in practice could result in an increased risk of stroke as the exposed plaque material can 
trigger the clotting cascade.23 
Shear-Induced Targeting 
In advanced atherosclerosis, the affected vessels can become stenosed due to outward 
(toward the lumen) growth of the intima.  This stenosis, or narrowing of the blood vessel, results in 
increased blood shear stress over the plaque due to increased blood velocity.  This unique high 
shear, and in many cases disturbed, flow environment creates an opportunity for shear sensitive 
NCs. Taking advantage of this effect, Home et al. designed “lenticular” (lentil-shaped) liposomes 
which were found to deform in response to high shear, releasing their drug cargo.24 These liposomes 
specifically responded to the high-shear environment found in highly occluded atherosclerotic 
vessels in an in vitro environment, releasing their cargo at these sites. However, it is worth nothing 
that experiments in this study were performed in a buffer solution (reasonably, for the sake of 
simplicity), and further trials in human blood and in an in vivo environment would yield more 
information about the efficacy of such carriers. Employing a different strategy, Korin et al. developed 
shear-activated nanotherapeutics (SA-NTs), micron-scale aggregates of NCs which become 
disaggregated under high shear conditions.25 These SA-NTs were shown to disaggregate when 
entering highly-occluded vessels both in vitro and in vivo. Further, the SA-NTs were loaded with a 
fibrolytic drug to explore their effectiveness in treatment of thrombosis, and greatly improved the 
survival time for mice with induced thrombosis. 
Overall, it is clear that enhanced permeability is present in some capacity in atherosclerosis 
though likely not as robust as has been described in cancer, and there may be methods for taking 
advantage of this phenomenon more fully. As material design becomes more advanced and the 
interaction between particular materials and blood cells is more fully understood, researchers will 
have a wide array of materials to choose from when designing drug carriers, with varying degrees of 
protection from clearance. Aside from further investigation of zwitterionic materials, researchers 
can also consider masking their carriers by mimicking various cells, such as platelets, as shown in a 
recent study by Hu et al.26 The authors directly coated PLGA nanoparticles with a platelet plasma 
membrane, which they described as “cloaking.” The platelet membrane-cloaked PLGA nanoparticles 
(PNPs) demonstrated decreased macrophage internalization and complement activation, preventing 
their recognition by the body’s immune response. Further, the use of “guiding” via magnetic fields 
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can assist in localizing drug carriers to the site of disease, increasing the accumulation of NCs in the 
diseased tissue. 
Inflammatory biomarkers for active targeting of specific cells 
Although a number of studies have successfully explored the use of “passively” targeted 
NCs, there is great interest in increasing drug carrier specificity and efficacy through the use of 
“actively” targeted NCs, which are able to preferentially bind to specific cellular markers present in 
diseased states. Such design strategies are discussed in detail below. 
Endothelial cells 
Inflammation is an immune response that becomes unregulated and exaggerated during 
atherosclerosis. Specifically, lipid accumulation promotes the overexpression of adhesion receptors 
by endothelial cells that leads to the recruitment of platelets, leukocytes, and smooth muscle cells.3 
Therefore, decorating the nanoparticle surface with ligands/antibodies specific for an overexpressed 
inflammatory molecule in atherosclerosis has been widely implemented as a targeting approach (see 
Figure 3). In general, ECs are a highly attractive target for NCs in vascular diseases as they are 
directly accessible from the bloodstream, rather than from within the forming atherosclerotic 
plaque. We have extensively evaluated the adhesion of drug carriers to inflamed HUVECs targeting 
E-selectin, ICAM-1, and VCAM-1 adhesion receptors involved in leukocyte adhesion and 
transmigration. Decorating the surface of nanoparticles with sialyl Lewisa (sLea) targeting ligand or 
anti-ICAM-1 antibody showed that nanoparticles are able to bind activated human umbilical vein 
endothelial cells (HUVECs) in in vitro parallel plate flow chamber experiments but have difficulty 
marginating and localizing to the endothelial surface compared to microparticles.27 To improve the 
adhesion of nanoparticles, we examined the effect of PEGylation using the two receptor-ligand 
targeting mechanisms. It was interesting to find that PEGylation improved the adhesion of aICAM-1 
nanoparticles but did not improve the performance of sLea polystyrene.28,29 This discrepancy in the 
impact of PEG chains on particle adhesion was linked to the receptor-ligand kinetics, where the 
presence of PEG improved particle binding for ligand systems with weak kinetics. As such, it is 
important to understand the capability of receptor-ligand systems when targeting specific cells, 
especially since expression of surface receptors can vary throughout disease stages.  
Yang et al. decorated the surface of silica nanoparticles with anti-VCAM-1 monoclonal 
antibody. The study demonstrated VCAM-1 targeted nanoparticles were able to bind to sites of 
inflammation and were taken up by ECs.30 In a separate study by Calin et al., a peptide specific for 
the VCAM-1 receptor was attached to the surface of pegylated target-sensitive liposomes (TSLs) 
encapsulating a CCR2 agonist, which become destabilized when binding to target.31 VCAM-1 
targeted TSLs were able to specifically bind to activated ECs and immobilized VCAM-1 in vitro. These 
results were conducted mainly in a static environment and neglected physiological blood flow 
conditions that could potentially affect liposome stability. In situ studies with ApoE -/- mice 
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demonstrated that VCAM-1 targeted TSLs were able to efficiently bind to atherosclerotic aortas 
compared to non-targeted TSLs. 31  
The persistent presence of blood flow over the endothelium in healthy vessels means there 
is constant presence of flow-induced shear at the vascular wall, which has a significant impact on the 
adhesion dynamics of nanoparticles. As previously alluded to, the blood shear for plaques in 
different vessels can vary depending on the presence and extent of stenosis in the vessels. As such, 
there have been a number of studies exploring the effects of shear stress on the targeting and 
uptake efficiency of vascular-targeted NCs. Shear stress naturally results in a negative impact on the 
ability of targeted NCs to bind to the inflamed endothelium due to drag forces on the particle 
competing with binding forces,32 but can also impact the phenotype and function of endothelial 
cells. Malek et al. reported calcium- and tyrosine kinase-dependent endothelial cell shape change 
and F-actin filament rearrangement in response to shear flow.33 These cellular changes also appear 
to affect the uptake of targeted NCs via CAM-mediated endocytosis. Bhowmick et al. demonstrated 
that flow-conditioned endothelial cells exhibit delayed CAM-mediated endocytosis of NCs targeted 
to ICAM-1, and hypothesized that this delayed uptake is related to the rearrangement of the actin 
cytoskeleton of the ECs.34 Similarly, Han et al. demonstrated that flow-conditioned ECs exhibited 
reduced uptake of PECAM-1 targeted NCs, and that this reduced uptake was linked to the 
rearrangement of actin stress fibers in the ECs.35 Perhaps more interestingly, this same study 
showed that acute shear stress stimulates the uptake of PECAM-1 targeted NCs, while chronic shear 
stress (under which the ECs become elongated) decreases uptake, suggesting that acute shear stress 
likely stimulates a separate mechanism of NC internalization. A follow-up study confirmed that this 
effect involves mechanosensing of shear stress in cholesterol-rich regions of the plasmalemma, and 
also suggested the importance of both RhoA/ROCK signalling pathways and Src family kinases.36   
Macrophages 
Macrophages are an important component in atherosclerosis disease progression because 
of their role in oxidized lipid uptake leading to their differentiation into foam cells, which secrete 
inflammatory cytokines maintaining the inflammatory disease state. Petersen et al. describe 
amphiphilic nanoparticles that have the potential to inhibit lipid uptake by macrophages and 
preventing their differentiation into foam cells. The authors fabricated nanoparticles comprised of a 
mucic acid core and mucic acid- PEG shell.37 The mucic acid component was used to target scavenger 
receptors on macrophages, such as SR-A and CD36, which normally bind lipids. The amphiphilic 
nanoparticles had the ability to inhibit lipid uptake by competitively binding receptors and 
decreasing scavenger receptor surface expression.37 Iverson et al. also used mucic acid nanoparticles 
to target scavenger receptors of inflammatory macrophages. The macromolecules lowered oxidized 
low density lipoprotein (oxLDL) accumulation by 88%. In vivo experiments in rats demonstrated a 
decrease in the cholesterol accumulation and macrophage retention by usage of mucic acid 
nanoparticles.38 Another recent study by Bagalkot et al. utilized hybrid lipid-latex (LiLa) nanoparticles 
to target M1 inflammatory macrophages. Their results suggested that LiLa nanoparticles can 
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preferably target inflammatory macrophages in atherosclerosis and obesity models39 and 
demonstrated that macrophages are a potential target for treating and detecting inflammatory 
diseases.  
High-density lipoprotein (HDL) helps move cholesterol from macrophages to the liver through a 
reverse cholesterol transport mechanism.40 Despite the poor understanding of this reverse transport 
process, the resulting protection against atherosclerosis has inspired nanoparticle mimics for 
therapy in this disease. HDL contains a lipid hydrophobic core coated with phospholipids and 
apolipoproteins (ApoA-I or Apo-II). Sanchez-Gaytan et al. incorporated this phenomenon into their 
particle design by fabricating HDL-PLGA nanoparticles. The nanoparticles consisted of a PLGA core 
coated with phospholipids and apolipoproteins (ApoA-I). The HDL-PLGA nanoparticles interacted 
preferentially with macrophages in incubation assays and were found to localize with macrophages 
with in atherosclerotic aortas.40 Duivenvoorden et al. produced a statin-loaded reconstituted HDL 
nanoparticle displaying loss of cell viability in macrophages through decreased proliferation and non-
apoptotic cell death.41 In vitro and in vivo apoE-KO mice studies demonstrated an accumulation of 
statin-loaded rHDL nanoparticles within plaque macrophages, which was attributed to the enhanced 
permeability of the diseased tissue. The authors also mentioned the possibility of rHDL interacting 
with scavenger receptor B1 and other components employed by native HDL in cholesterol transport 
or macrophage phagocytosis as alternative pathways for accumulation within atherosclerotic 
plaque.  
Many groups have also explored the use of nanoparticle systems for targeting macrophages 
to deliver contrast agents for plaque detection. Early detection of atherosclerotic plaques can allow 
clinicians to deliver therapeutics before plaque rupture and thrombus formation. Dextran sulfate, 
another ligand for SR-A, was used to coat iron oxide nanoparticles for binding macrophages with the 
goal of delivering a contrast agent for imaging within the plaque, i.e. macrophages internalize bound 
contrast-loaded nanoparticles and migrate into the plaque.42 Nie et al. specifically targeted the CD36 
receptor in both mouse and human macrophages using nanovesicles decorated with oxidized 
phosphatidylcholine.43 The targeted nanovesicles demonstrated higher binding and uptake by 
macrophages in vitro. The in vivo studies carried out in atherosclerotic (LDLr -/-) mice provided 
evidence that the targeted nanovesicles were co-localized with intima macrophages specifically 
through the CD36 receptor. This approach allows for the imaging of atherosclerotic plaques to 
evaluate the accumulation and distribution of macrophages.43 Marrache et al. developed high 
density lipoprotein (HDL)-mimicking nanoparticles to target macrophage apoptosis for delivering 
contrast agents for detection of vulnerable plaques.44 These nanoparticles were made up of a core 
comprised of biodegradable PLGA, cholesteryl oleate and a phospholipid bilayer and were decorated 
with triphenylphosphonium(TPP), a cation for detecting the collapse of mitochondrial membrane 
during apoptosis. Fluorescent microscopy, flow cytometry data and in vivo experiments in rats 
showed the success of these particles for detecting apoptotic macrophages in comparison to non-
targeted particles. These particles have also the potential to enhance atheroprotection by delivering 
HDL to macrophages.44 Spyropoulos-Antonakalis et al. used polyamidoamine dendimers for delivery 
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of ZnPc photosensitizing (PS) molecules for photodynamic therapy of cardiovascular disease to 
macrophages responsible for atheromatous plaque growth.45 Irradiation of the atheromatous plaque 
at specific wavelength activates PS molecules inducing cell necrosis and inhibiting activity of the 
macrophage cells responsible for plaque growth. 
 In summary, all mentioned studies demonstrate the importance of macrophages as a 
potential target for detection and treatment of cardiovascular inflammatory disease specifically in 
atherosclerosis. However, it is yet to be understood how researchers may take full advantage of 
macrophages’ natural functions (phagocytosis of excess LDL, as well as other immune cells) in order 
to more effectively design therapies for cardiovascular disease. In particular, it remains unclear 
whether therapeutics should be directed toward the macrophages themselves, i.e. reducing their 
accumulation, or whether macrophages should serve as a microscale delivery vehicle for 
nanoparticles containing drugs directed towards other critical components of the atherosclerotic 
plaque.  In the case of the latter, careful choice of the specific therapeutics to be delivered and the 
NC (type/design) would be required to ensure drug with retained activity can be released by 
macrophages into the plaque.  
Platelets 
Platelets experience increased adhesion to the vascular wall in atherosclerosis due to the 
tissue damage conferred by oxidized lipids, which propagates the inflammatory process and 
eventually lead to recruitment of smooth muscle cells (SMCs).3 This prominence of platelets in the 
progression of atherosclerosis makes platelet targeting a potentially attractive option for delivering 
therapeutics and imaging agents. 
One targeting approach involving platelets is to directly bind nanoparticles to platelet 
surface receptors. Jacobin-Valat et al. fabricated Versatile Ultrasmall SuperParamagnetic Iron Oxide 
(VUSPIO) nanoparticles conjugated to recombinant human antibody targeting activated platelets, 
rIgG4 TEG4.46 The specificity of rIgG4 TEG4 for the αIIbβ3-complex, present on platelet membrane, 
was examined using immunohistochemistry on murine and human atheromas, which proved to be 
similar to murine antibody, AP-2, that binds αIIb and β3 glycoproteins. Ex vivo ApoE-/- mice 
experiments demonstrated targeted VUSPIO nanoparticles localized within atherosclerotic vessel 
wall. The study also pointed out that platelets co-localized in areas rich in macrophages. A previous 
study by Jacobin-Valat incorporated an anti-human P-selectin antibody to the VUSPIO surface; in this 
case, the nanoparticles accumulated on the surface of and within activated platelets.47 Bachalet-
Violette et al. targeted P-selectin by coating superparamagnetic iron oxide (SPIO) nanoparticles with 
fuciodan, a sulfated polysaccharide that binds P-selectin. Fucoidan-SPIO nanoparticles were able to 
specifically bind activated platelets in citrated whole blood conditions.48 Several of these studies 
combined imaging techniques, such as the use of iron oxide nanoparticles, and ligands specific for 
activated platelet surface receptors to image atherosclerotic lesions with MRI approaches. However, 
the potential flaw with these studies is the lack of concrete evidence of the specificity of targeted 
nanoparticles to platelets rather the endothelium, which also express P-selectin.  In general, the 
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platelet targeting approach in atherosclerosis is supported by very loose evidence of platelet-
leukocyte interaction in atherosclerosis. As such, this approach of platelet targeted NCs may only be 
useful in cases of plaque rupture where extracellular material is exposed and facility platelet 
adhesion.   
Multi-targeted nanocarriers 
One new technique is the design of nanoparticles that exhibit multiple inflammatory cell 
characteristics. For instance, Anselmo et al. developed nanoparticles that mimic the discoidal shape, 
flexibility, and receptor surface expression of platelets. The nanoparticles were fabricated with PAH 
and BSA bilayers, where PAMAM dendrimers conjugated to three different targeting moieties were 
reacted to the surface.49 The three moieties included a collagen binding peptide, von Willebrand 
Factor (VWF) binding peptide, and a linear fibrinogen-mimetic peptide targeted to collagen, secreted 
VWF by endothelium, and integrin GPIIb-IIIa on activated platelets, respectively. The multivalency of 
these particles allowed them to interact with the injured endothelium and activate circulating 
platelets causing them to accumulate.49 Hyaluronic acid (HA) is a molecule that specifically binds to 
stabilin-2 and CD44 receptors used by Lee et al to formulate HA nanoparticles.50 Stabilin-2 has been 
shown to be overexpressed by macrophages, smooth muscle cells, and endothelial cells, while CD44 
is expressed by activated macrophages found in plaques. The study demonstrated that HA 
nanoparticles were capable of targeting atherosclerotic plaques through receptor-mediated 
endocytosis, specifically localizing in areas of stabilin-2 and CD44 overexpression. These two 
examples demonstrate that potential of targeting multiple cells, which could improve localization to 
atherosclerotic tissues due to the collection of cells involved. 
The dynamics of leukocyte binding are dependent on the interaction of ligands with multiple 
receptors. Therefore, several studies have focused on targeting multiple receptors as an efficient 
approach to increase the targeting efficiency of drug carriers. Eniola et al. used leukocyte-mimicking 
particles functionalized with sialyl LewisX (sLeX), and an antibody against ICAM-1, anti-ICAM-1 for 
simultaneous targeting of selectin and intercellular cell adhesion molecule-1 receptors.51 Their 
results demonstrated that only dual-targeted nanoparticles exhibit tight binding to the substrate 
under flow conditions as they mimic leukocyte binding dynamics more closely.51  Another study by 
Rafat et al. using polyvinyl alcohol hydrogels showed that conjugation of these hydrogels with anti-
VCAM1 and anti-E-Selectin in a 1:1 ratio resulted in increased adhesion to HUVECs compared to the 
case where anti-VCAM1, or anti-E-Selectin were used alone.52 McAteer et al. developed dual 
targeted microparticles of iron oxide  (MPIO) mimicking leukocyte adhesion by targeting both 
vascular cell adhesion molecule-1 (VCAM-1) and P-selectin in a mouse model of atherosclerosis. 
Their data showed that dual-targeted nanoparticles had 5-7 fold higher in vitro binding and 3-5 fold 
higher in vivo binding to endothelial cells than P-selectin-MPIO or VCAM-MPIO alone.53 Another 
study used PLGA nanoparticles conjugated with PEG, glycoprotein 1b (Gb1b) and trans-activating 
transcriptional (TAT) peptide to target P-selectin and von Willebrand Factor of inflamed endothelial 
cells.54 Their results indicated increased binding to human aortic endothelial cells under shear flow 
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from 40% for particles conjugated with single ligand to 70% for multi-ligand particles. Studying 
intima stenosis inhibition of the dextran-loaded particles also indicated that dual-targeted 
nanoparticles can result in equivalent stenosis inhibition at much lower concentrations than free 
dextran solution.54 A recent study by Papademetriou et al. compared the efficiency of single, double 
and triple targeted polystyrene particles functionalized with intercellular (ICAM-1), platelet-
endothelial (PECAM-1), and/or vascular (VCAM-1) cell adhesion molecules. ICAM-1 and PECAM-1 
utilize CAM-mediated endocytosis and VCAM-1 is active in clathrin-mediated endocytosis pathways. 
Their results demonstrated that triple targeted nanoparticles enhanced selectivity in disease 
conditions, internalization by cells, and in vivo targeting efficiency.55 
Another recent technique called collaborative enhancement of antibody binding utilizes the 
increased binding of antibodies (Abs) to epitopes of platelet cell adhesion molecule-1 (PECAM-1) by 
pairing them with a second antibody binding to a different adjacent epitope.56 This phenomenon is 
believed to occur because of the conformational and accessibility change of one epitope as a result 
of the attachment of another distinct epitope. 56 Chacko et al. have shown that this paired 
interaction between Abs coated on polystyrene NCs targeting distinct adjacent epitopes of PECAM 
will increase the binding of NCs and the effect is even more pronounced on multivalent carriers than 
free Abs.57 Pre-treatment with Ab2h anti-PECAM Ab enhanced the in vitro binding of Ab1h/NC to 
endothelial cells by this paired interaction specifically at high Ab1h densities and under flow 
conditions.  In vivo studies in mice also showed that the presence of Ab2m antibody enhances 
pulmonary uptake of Ab1m/125I-NC by 5.4 times. The reversed effect was also observed showing 
doubled Ab2m/125I-NC binding in the presence of Ab1m.57 These studies show the potential of this 
newly introduced technique to improve the binding of drug carriers. 
All of the studies above show that targeting more than one receptor or cell type 
simultaneously improves the therapeutic performance of particles either by making them adhere 
more tightly to their target cells or giving them the ability to bind to different cells which are 
involved in a diseased state. Further, a full understanding of the microenvironment and phenotype 
associated with a particular cardiovascular disease allows researchers to attach ligands for the key 
markers associated with said disease, allowing for much more selective and specific targeting. It is 
also important for researchers to understand possible spatial/steric limitations to multi-targeted 
approaches, as specific markers could be expressed either too close to one another or too far away 
from one another to allow multi-targeting to make a difference. This approach, of course, can lead 
to reduced systemic side effects for therapeutics and reduced background signal for imaging agents. 
It would be prudent for researchers to design their particulate carriers using a variety of ligands with 
a range of ligand ratios, in order to optimize the effectiveness of their carrier. 
Targeting extracellular matrix components, proteins, and other cell types 
Oftentimes, when stents are surgically placed in order to unblock an occluded atherosclerotic artery, 
the endothelium becomes damaged, resulting in the exposure of collagen (the major constituent of 
the extracellular matrix), which then allows for platelets to accumulate and potentially form 
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dangerous clots or result in restenosis.58 McMasters and Panitch examined the ability of collagen-
directed thermosensitive nanoparticles to prevent platelet adhesion and activation following stent 
placement. The authors incubated platelets and collagen-targeted nanoparticles in plasma over a 
collagen-coated plate. Measuring the concentrations of two platelet activation factors released, it 
was observed that collagen-targeted nanoparticles inhibited platelet activation by about 60%.58 This 
study displays a competitive inhibition where the targeted nanoparticles bind the collagen before 
the platelets are able to, reducing platelet activation. It is important to note, however, such collagen 
targeting nanoparticles can only be used prophylactically in clinical situation where denudation of 
the endothelium is anticipated, e.g. in stent placement.  Kamaly et al. employed the concept of 
targeting collagen exposed on inflamed vascular sites to deliver an anti-inflammatory peptide to 
reduce the risk of continued inflammation and restenosis.59 The nanoparticles encapsulating the 
anti-inflammatory peptide consisted of PLGA-PEG chains with collagen IV targeting ligand, 
conjugated to the end of the PEG chains. The study demonstrated that these nanoparticles had the 
capability to improve resolution and reduce inflammation in in vivo mouse models of peritonitis and 
hind-limb ischemia reperfusion, respectively.59 As previously discussed in the context of creating 
long-circulating particles, Hu et al. coated PLGA nanoparticles (PNPs) with a platelet plasma 
membrane as a “cloaking” system.26 These PNPs also showed preferential adhesion to sites of 
diseased vasculature where collagen was exposed. Another protein found at vascular injury sites is 
fibrin, which is shown to accumulate after an atherosclerotic plaque is removed, promoting 
restenosis.60 Gu et al. studied the targeting ability of fibrin-targeted layered double hydroxide (LDH) 
nanoparticles conjugated to low molecular weight heparin (LMWH) to arterial injuries of rats. A 
comparison between injured and uninjured arteries demonstrated that fibrin-targeted LDH 
nanoparticles successfully bound at injury sites and delivered LMWH, which reduced luminal loss 
and thrombotic occlusion.60 Other components involved in atherosclerosis treatment are high-
density lipoproteins and statins, which are currently the gold standard for preventing or decelerating 
atherosclerosis.2 As discussed above, there are numerous biomarkers presented in atherosclerosis 
that can be taken advantage of when designing targeted drug delivery systems. Further, many 
groups are finding success by taking inspiration from the body’s natural processes, designing their 
carriers to mimic blood components or take advantage of the natural function of cells to deliver their 
drug carriers to the target site. While the choice of targeting strategy is highly important to the 
design of effective VTCs, NC physical properties such as size, shape, and density heavily influence the 
effectiveness of particle drug carriers in traveling and binding to the vascular endothelium. These 
effects are discussed in detail below. 
Effect of Carrier Physical Properties on Vascular Wall Margination and Targeting Efficiency 
 Intravenously administered vascular-targeted NCs will interact with cells in the bloodstream 
en route to their target destination, and must effectively marginate, or localize, to the vascular wall 
and bind in order to reach the disease site. In the absence of effective margination, vascular-
targeted NCs are rendered useless. There are a number of factors that influence the ability of 
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particles to marginate to the vascular wall: particle size and shape, as well as the size of the cell-free 
layer all have an effect on the margination efficiency of NC systems.1,61–63 
Effect of Carrier Size on Margination and Targeting Efficiency 
 A number of works have investigated the influence of carrier size on margination 
efficiency.63–67 Charoenphol et al. used parallel plate flow chamber (PPFC) assays to demonstrate 
that spherical, vascular-targeted particles in the 2-5µm diameter size range adhere with much 
greater efficiency than their nano-sized counterparts, likely due to preferential collision dynamics in 
blood flow.63 This result was replicated in a follow-up in vivo study, where targeted particles of 
varying sizes were intravenously injected into atherosclerotic mice; again, the group found that 2µm 
particles outperformed nanoparticles in reaching and binding to the endothelial cell lining of the 
aorta in these animals. Namdee et al. later showed in parallel plate flow chamber experiments that 
poor nanoparticle adhesion is directly linked to poor margination, where nano-sized particles instead 
become entrapped in the red blood cell core (see Sidebar 1), and that a disproportionally high 
concentration of NCs would be required to achieve the same adhesion as micron-sized particles.68 
This result was replicated by Lee et al.69 and Müller et al.64,70, both computationally and 
experimentally. It is important to note, however, that Charoenphol et al. also demonstrated reduced 
adhesion efficiency for larger particles under high shear conditions, due to the increased shear 
forces acting on a larger particle at the vascular wall.  
 Some recent works have shown an opposite trend. Patil et al. observed a decrease in particle 
adhesion in high-shear flow with increasing particle diameter from 5µm to 20µm.71 Toy et al. 
observed reduced margination efficiency with increased sized in a series of microfluidic in vitro 
experiments with particles ranging in size from 60nm to 130nm66, and Jurney et al. saw a similar 
trend for particles ranging in size from 60nm to 970nm.65 These works seem to suggest that larger, 
heavier particles are more likely to settle due to gravitational forces, and that increasing shear forces 
acting on larger particles greatly reduce their adhesion efficiency. However, all of these works 
examined margination and adhesion in buffer flow, rather than human blood flow. It is now known 
that collisions between red blood cells and particulate carriers greatly influence particle 
margination63,72, and this must be considered when designing vascular-targeted NCs.  
Effect of Carrier Shape on Margination and Targeting Efficiency 
 In recent years, groups have begun to explore shape as a key property in drug carrier 
design.73 It is long known that differently shaped particles behave differently under flow conditions; 
thus, a number of groups have investigated how shape might influence the ability of particles to 
marginate in blood flow.61,66,74,75 Thompson et al. compared spherical carriers to ellipsoidal (rod-
shaped) particles of varying aspect ratios in in vitro parallel plate flow chamber assays using human 
blood and in vivo in ApoE-/- mice and found that rod-like particles with equivalent spherical 
diameter (ESD) greater than 1µm outperformed their spherical counterparts.61,76 However, rod-like 
particles with ESD less than 1µm exhibited little to no improvement in margination and adhesion 
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efficiency relative to equivalent spheres. This suggests that, below a certain size, particles of all 
shapes are unable to effectively marginate to the vascular wall, but above a certain threshold, 
elongated particles may be able to marginate and adhere more effectively. Similarly, Wen et al. 
investigated the ability of icosahedral particles (approximating spheres) and rod-like particles loaded 
with imaging agents to accumulate at sites of thrombus formation, finding that the rod-like particles 
were much more efficient in this regard.75 Further, Toy et al. showed that rod-shaped nanoparticles 
outperformed spherical nanoparticles in in vitro adhesion assays performed in buffer flow.66 The fact 
that red blood cells were absent in assays from the Toy work highlights the critical function of 
particle-cell dynamics in margination, as discussed earlier. 
 Computational studies have also explored the effect of carrier shape on margination and 
adhesion efficiency. Vahidkhah et al. constructed a 3D computational fluid dynamics model to 
simulate margination, wall contact, and adhesion of particulate carriers of varying shapes, including 
spherical, oblate, and prolate particles.74 Interestingly, their study found that shape influences 
margination and adhesion efficiency differently. The oblate particles were most effective at 
marginating toward the vascular wall, due to their increased collision frequency with RBCs and 
rotation in flow. However, once present in the cell-free layer close to the vascular wall, prolate 
particles were most likely to make contact with the wall due to their elongated shape. Finally, oblate 
particles were most effective at forming firm adhesive contact, due to a large contact surface area. 
This work strengthens and supports previous experimental studies and sheds some light on the 
various effects at play in blood flow. 
 Although only a handful of works are highlighted here in order to provide some context, 
many more studies have been performed to elucidate the effect of shape on particle margination 
and adhesion efficiency. For a more in-depth review on the effects of particle shape on carrier 
effectiveness, see Fish et al.77 
Effect of Carrier Density on Margination and Targeting Efficiency 
 To date, the bulk of NCs used for vascular-targeting are essentially neutrally buoyant or only 
slightly denser than blood, including liposomes and most biodegradable polymeric NCs. Recently, 
Thompson et al. reported density as a potential avenue for enhancing vascular wall margination of 
NCs in human blood flow, where silica nanoparticles with twice (~2 g mL-1) the density of blood were 
shown to exhibit > 3 folds higher adhesion to vascular wall endothelial cells compared to neutrally 
buoyant polystyrene nanoparticles of the same size and targeting ligand in in vitro assays with 
human blood flow.78 The authors show via confocal microscopy that this enhanced performance by 
silica nanoparticles was due to the presence of red blood cells promoting enhanced margination for 
silica relative to buffer flow while the density neutral polystyrene exhibit negative margination in the 
presence of red blood cells. Interestingly, titania nanoparticles of the same size and targeting 
characteristics but with four times (~3.9 g mL-1) the density of blood did not marginate differently 
from polystyrene ones, suggesting that their perhaps is an optimal particle density for which 
interaction with cells in blood, particularly red blood cells, results in maximum displacement to the 
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vascular wall.  However, in a study by Toy et al., particle density was found to have a negative impact 
on margination, where less dense nanoparticles exhibited significantly higher margination than 
dense ones in simple buffer flow, which was attributed to larger particles carrying a larger 
momentum in flow. Again, the key difference between the work by Toy et al. and Thompson et al. is 
the presence of red blood cells, highlighting the importance of cell-particle collision in margination in 
blood flow.66  More work would need to be done, however, to fully flesh out the utility of density to 
enhance the margination of NCs.  One limitation to this is the limited availability of nanoparticles 
with a wide range of density to explore.  In this regard, computational modeling might be beneficial 
for bridging the gap. Another potential limitation to use of density as a parameter for vascular-
targeting of NCs is the fact that the bulk of the biocompatible materials available for construct of 
dense NCs, including iron oxide (∼5 g mL−1) and gold (∼19 g mL−1), are not conducive to drug loading. 
Sidebar title: The Margination Problem 
The fluid mechanics of blood flow (termed hemodynamics) are quite complex, due to the 
heterogeneous nature of blood. Interactions between blood cells create some interesting effects. 
Due to the laminar flow profile and the physical properties of red blood cells (RBCs), a “red cell core” 
is formed along the centerline of blood flow, with very few red cells flowing close to the endothelial 
surface. Nanocarriers often become trapped within this core, unable to travel (marginate) to the 
vascular wall, and there is evidence that suggests that smaller particles are more prone to inhibited 
margination.1 Thus, researchers designing vascular-targeted carriers should be wary of the 
assumption that smaller particles will always perform better due to increased transmigration ability. 
Conclusion 
 Many of the successful strategies used by researchers designing vascular-targeted NCs 
involve designing bio-mimetic carriers, or carriers that take advantage of the natural function of 
native cells in the disease state. The successful use of such tactics highlights the need for a deeper 
understanding of the physiology present in cardiovascular disease. Taking inspiration from nature, 
we can design more effective drug carriers that will result in a larger therapeutic benefit in 
cardiovascular disease. This “reverse-engineering” of physiological systems in order to produce a 
therapeutic benefit is a common, emerging theme in the biological sciences, and could prove to be 
very useful in carrier design. It is crucial for researchers to consider both the physical properties of 
VTCs and the effectiveness of various targeting schemes when designing VTCs, which presents quite 
the challenge for researchers. However, emerging technologies from the materials science realm are 
providing more control over carrier physical properties, but it can still be quite difficult to achieve a 
particle drug carrier with optimized size, shape, and density, as well as readily available groups for 
conjugate chemistry. This is most clear in the discussed importance of the physical characteristics of 
the NC in vascular targeting; NCs must be small enough to navigate the vasculature and readily 
transmigrate across biological barriers, but very small NCs have been shown to exhibit difficulties in 
marginating from the center of blood flow to the vascular wall.  
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Another factor to keep in mind is the potential clinical utility for a particular drug carrier 
design. In this context, it is beneficial to consider the utility of nanoscale drug carriers in chronic 
versus acute conditions, for instance. While it is potentially possible to deliver a number of 
therapeutic agents for treating chronic conditions via vascular targeted carriers, researchers must 
consider the potential physiological impact of repeated or continuous injections of a particular drug 
carrier, and whether there are any negative consequences that outweigh therapeutic benefit. These 
considerations are discussed in more detail in a recent review by Howard et al.81 
Additionally, through examination of recent literature, a number of important aspects of the 
design of vascular-targeted NCs for cardiovascular disease come to light. In particular, carrier 
parameters such as carrier size, shape, and material must be considered in order to design a carrier 
that effectively marginates from the red cell core to the vascular wall and binds to its target. These 
parameters are critical for the successful use of vascular-targeted NCs.  
Further, NCs will always have to combat immunological clearance mechanisms (such as 
phagocytosis by white blood cells), which may be mitigated to some extent by the use of protective 
coatings such as PEG or zwitterionic coatings. Finally, there are recently highlighted limitations in the 
animal models used to evaluate the efficacy of vascular-targeted NCs as therapeutics. Our group has 
shown that vascular-targeted carriers can perform very differently in a mouse versus a human due 
to the differences in hemodynamics between humans and animals.82 Furthermore, differences in 
plasma proteins between animal models are now known to have varying impacts on the 
performance of targeted NCs.83 In particular, it seems that commonly-used mouse models may not 
accurately capture the interactions between NCs and plasma proteins in humans, while porcine 
models may provide a more complete picture. These limitations, together, create a balance of 
factors that is very important to consider in the design of novel targeted NCs. 
Notes 
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Figure 1: Particle-cell dynamics in blood flow and their influence on margination. Nanosized carriers, 
both spherical and rod-like, are more likely to become entrapped in the RBC core, and are unable to 
effectively marginate to the vascular wall. Larger particles, 1-2µm in size, are pushed toward the cell-
free layer, where they are able to interact with the endothelium. Rod-like microparticles may exhibit 
enhanced margination due to an increased drift force and tumbling motion in flow. 
Figure 2: Passive targeting approach for cardiovascular diseases. Inflammation and endothelial 
dysfunction are characteristics demonstrated by damaged vascular tissues. Here are displayed four 
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types of nanoparticles that take advantage of the “Enhanced Permeability Effect (EPR).” One 
drawback of this approach is that the particle may become cleared before reaching the diseased 
endothelium. The addition of PEG and zwitterions to the surface of the particles has shown to 
decrease plasma protein adsorption increasing circulation time and decrease clearance. The third 
approach depicted is the application of a magnetic field used to direct nanoparticles throughout the 
body.  
Figure 3: Depiction of atherosclerotic plaque and nanoparticle active targeting mechanisms. During 
atherosclerosis, the endothelial cells become inflamed as low-density lipoproteins (LDLs) 
accumulate. LDLs are oxidized and taken up by macrophages, which then differentiate into foam 
cells. Inflammatory molecules are released promoting leukocyte and platelet adhesion leading to 
smooth muscle cell recruitment. Shown are three active targeting mechanisms: (a) targeting of 
inflammatory surface receptors, (b) multivalent targeting of exposed collagen (post-surgical 
intervention) and platelets, and (c) high-density lipoprotein mimetic targeting utilizing the reverse 
cholesterol transport mechanism. NP=nanoparticle. 
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Table 1—Summary of Targeting Schemes and their Advantages and Disadvantages 
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